These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 35405741)

  • 21. Small molecule AZD4635 inhibitor of A
    Borodovsky A; Barbon CM; Wang Y; Ye M; Prickett L; Chandra D; Shaw J; Deng N; Sachsenmeier K; Clarke JD; Linghu B; Brown GA; Brown J; Congreve M; Cheng RK; Dore AS; Hurrell E; Shao W; Woessner R; Reimer C; Drew L; Fawell S; Schuller AG; Mele DA
    J Immunother Cancer; 2020 Jul; 8(2):. PubMed ID: 32727810
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Radiofrequency ablation in combination with CD73 inhibitor AB680 reduces tumor growth and enhances anti-tumor immunity in a syngeneic model of pancreatic ductal adenocarcinoma.
    Faraoni EY; Strickland LN; O'Brien BJ; Barraza JF; Thosani NC; Wray CJ; Mills TW; Bailey-Lundberg JM
    Front Oncol; 2022; 12():995027. PubMed ID: 36147911
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor immunity is defective in T cell-specific microRNA-155-deficient mice and is rescued by immune checkpoint blockade.
    Huffaker TB; Lee SH; Tang WW; Wallace JA; Alexander M; Runtsch MC; Larsen DK; Thompson J; Ramstead AG; Voth WP; Hu R; Round JL; Williams MA; O'Connell RM
    J Biol Chem; 2017 Nov; 292(45):18530-18541. PubMed ID: 28912267
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD39/CD73/A2AR pathway and cancer immunotherapy.
    Xia C; Yin S; To KKW; Fu L
    Mol Cancer; 2023 Mar; 22(1):44. PubMed ID: 36859386
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor intrinsic and extrinsic functions of CD73 and the adenosine pathway in lung cancer.
    Kowash RR; Akbay EA
    Front Immunol; 2023; 14():1130358. PubMed ID: 37033953
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Local and Targeted Delivery of Immune Checkpoint Blockade Therapeutics.
    Han X; Li H; Zhou D; Chen Z; Gu Z
    Acc Chem Res; 2020 Nov; 53(11):2521-2533. PubMed ID: 33073988
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intratumoral immunotherapy using a TLR2/3 agonist, L-pampo, induces robust antitumor immune responses and enhances immune checkpoint blockade.
    Lee WS; Kim DS; Kim JH; Heo Y; Yang H; Go EJ; Kim JH; Lee SJ; Ahn BC; Yum JS; Chon HJ; Kim C
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764365
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Small Molecule Antagonist of PD-1/PD-L1 Interactions Acts as an Immune Checkpoint Inhibitor for NSCLC and Melanoma Immunotherapy.
    Wang Y; Gu T; Tian X; Li W; Zhao R; Yang W; Gao Q; Li T; Shim JH; Zhang C; Liu K; Lee MH
    Front Immunol; 2021; 12():654463. PubMed ID: 34054817
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adenosinergic axis and immune checkpoint combination therapy in tumor: A new perspective for immunotherapy strategy.
    Liu Z; Liu X; Shen H; Xu X; Zhao X; Fu R
    Front Immunol; 2022; 13():978377. PubMed ID: 36159861
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL.
    Zhang T; Liu H; Jiao L; Zhang Z; He J; Li L; Qiu L; Qian Z; Zhou S; Gong W; Meng B; Ren X; Zhang H; Wang X
    J Immunother Cancer; 2022 Apr; 10(4):. PubMed ID: 35365585
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intratumoral CD73: An immune checkpoint shaping an inhibitory tumor microenvironment and implicating poor prognosis in Chinese melanoma cohorts.
    Gao Z; Wang L; Song Z; Ren M; Yang Y; Li J; Shen K; Li Y; Ding Y; Yang Y; Zhou Y; Wei C; Gu J
    Front Immunol; 2022; 13():954039. PubMed ID: 36131912
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CD73 as a potential opportunity for cancer immunotherapy.
    Ghalamfarsa G; Kazemi MH; Raoofi Mohseni S; Masjedi A; Hojjat-Farsangi M; Azizi G; Yousefi M; Jadidi-Niaragh F
    Expert Opin Ther Targets; 2019 Feb; 23(2):127-142. PubMed ID: 30556751
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibitory effect of adenosine on adaptive antitumor immunity and intervention strategies.
    Wang L; Zhang W; Zhang J; Zheng M; Pan X; Guo H; Ding L
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Sep; 52(5):567-577. PubMed ID: 37916308
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small molecular CD73 inhibitors: Recent progress and future perspectives.
    Ge GH; Wang QY; Zhang ZH; Zhang X; Guo S; Zhang TJ; Meng FH
    Eur J Med Chem; 2024 Jan; 264():116028. PubMed ID: 38086190
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Delivery of an ectonucleotidase inhibitor with ROS-responsive nanoparticles overcomes adenosine-mediated cancer immunosuppression.
    Mao C; Yeh S; Fu J; Porosnicu M; Thomas A; Kucera GL; Votanopoulos KI; Tian S; Ming X
    Sci Transl Med; 2022 Jun; 14(648):eabh1261. PubMed ID: 35675434
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effect of Curcumin on multi-level immune checkpoint blockade and T cell dysfunction in head and neck cancer.
    Liu L; Lim MA; Jung SN; Oh C; Won HR; Jin YL; Piao Y; Kim HJ; Chang JW; Koo BS
    Phytomedicine; 2021 Nov; 92():153758. PubMed ID: 34592487
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Combined PD-1 blockade and GITR triggering induce a potent antitumor immunity in murine cancer models and synergizes with chemotherapeutic drugs.
    Lu L; Xu X; Zhang B; Zhang R; Ji H; Wang X
    J Transl Med; 2014 Feb; 12():36. PubMed ID: 24502656
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Serum CD73 is a prognostic factor in patients with metastatic melanoma and is associated with response to anti-PD-1 therapy.
    Turiello R; Capone M; Giannarelli D; Morretta E; Monti MC; Madonna G; Mallardo D; Festino L; Azzaro R; Levesque MP; Imhof L; Weide B; Amaral T; Chevrier M; Sucker A; Rutkowski P; Schadendorf D; Lebbe C; Luke JJ; Wistuba-Hamprecht K; Dummer R; Pinto A; Morello S; Ascierto PA
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33361405
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CC-01 (chidamide plus celecoxib) modifies the tumor immune microenvironment and reduces tumor progression combined with immune checkpoint inhibitor.
    Chen JS; Chou CH; Wu YH; Yang MH; Chu SH; Chao YS; Chen CN
    Sci Rep; 2022 Jan; 12(1):1100. PubMed ID: 35058524
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumor-targeted interleukin-12 synergizes with entinostat to overcome PD-1/PD-L1 blockade-resistant tumors harboring MHC-I and APM deficiencies.
    Minnar CM; Chariou PL; Horn LA; Hicks KC; Palena C; Schlom J; Gameiro SR
    J Immunother Cancer; 2022 Jun; 10(6):. PubMed ID: 35764364
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.